The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA editing. Its aim is to treat an eye disease called wet age-related macular degeneration that causes vision loss in millions of older people worldwide.
This trial marks a new frontier in gene therapy – the process of treating or curing medical conditions by changing a person’s genes.
